Navigation Links
China Biologic to Report Second Quarter 2014 Financial Results

BEIJING, July 29, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second quarter 2014 financial results on Tuesday, August 5, 2014 after the market closes.

The Company's management will hold a conference call at 8:00 a.m. ET on Wednesday, August 6, 2014, which is 8:00 p.m., Beijing Time on August 6, 2014, to discuss second quarter 2014 results. Listeners may access the call by dialing:

US:                                                       1 877 870 4263 
International:                                        1 412 317 0790   
Hong Kong:                                          800 905 945 
China:                                                  400 120 1203
Passcode:                                            China Biologic Products Inc.                   

A telephone replay will be available one hour after the conclusion of the conference call through 9:00 a.m., Eastern Time on August 13, 2014. The dial-in details are:

US:                                                        1 877 344 7529
International:                                         1 412 317 0088    
Passcode:                                             10050434                      

A live and archived webcast of the conference call will be available through the Company's investor relations website at

About China Biologic Products, Inc.

China Biologic is a leading plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China. For additional information, please see the Company's website .


China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191

SOURCE China Biologic Products, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China
2. Orthopedic Instrument Industry in China Markets Forecast to 2015
3. EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
4. CareFusion Completes Vital Signs Acquisition In U.S., China
5. China Antidiabetic Drug Market 2014 Analysis & 2018 Forecasts
6. Research Report on Global and China Aerosol Industry, 2013-2017
7. Use of Roches Herceptin Among HER2+ Gastric Cancer Patients May Double in China Over the Next Three Years
8. China Pharmaceutical Guidebook: (2013 Edition) Latest Chinese Regulations for Imported Drug Registration
9. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
10. China Feed Additives Industry Report, 2012-2015
11. Lucintel Analysis: Medical Reforms and Aging Population to Offer Significant Growth Opportunities to China Oxygen Cylinders Industry Players
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):